Francisco Hernandez-Ilizaliturri, MD
Francisco Hernandez-Ilizaliturri, MD
Clinical Chief, Lymphoma & Myeloma
Professor of Oncology
Department of Medicine
Department of Immunology
Roswell Park Cancer Institute
Clinical Professor
Department of Medicine
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Areas of Expertise:
Lymphoma
Multiple myeloma
Chronic lymphocytic leukemia
Special Interests:
Mechanisms associated with resistance to monoclonal antibodies in lymphoma patients
Developing new strategies to enhance the activity of therapies such as rituximab and other monoclonal antibodies
Background
Education and Training:
MD - InstitutoTecnologico y de Estudio Superiores de Monterrey, Monterrey, Mexico
Residency:
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Fellowship:
Roswell Park Cancer Institute, Buffalo, NY
Board Certification:
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
- Ellis L, Lasorsa E, Smonskey M, Kirk J, Dalimov Z, Hernandez-Ilizaliturri F, Rosario S. Mitochondrial protection impairs BET bromodomain inhibitors mediated cell death and rovides rationale for combination therapeutic strategies. Accepted for publication. Cell Death and Disease. 2015
- Czuczman N, Barth MJ, Gu J, Neppalli V, Mavis C, Frys S*, Klener P, Vockova P, Czuczman MS, and Hernandez-Ilizaliturri FJ. Pevonedistat, a NEDD8 Activating Enzyme Inhibitor, is active in Mantle Cell Lymphoma and Enhances Rituximab Activity in vivo. Accepted for publication Blood 2015
- Xue K, Gu JJ, Zhang Q, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS, Guo Y. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. J Cancer Res Clin Oncol. Epub ahead of print 8/28/15. PMID: 26314218.
- Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabergas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. Am J Hematol. Epub ahead of print 6/4/15. PMID: 26044261
- Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H. Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw. 13(5):554-586, 2015. PMID: 25964641
- Barth M, Mavis C, Czuczman MS, and Hernandez-Ilizaliturri FJ. Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in pre-clinical models of mantle cell lymphoma. Clinical Cancer Research 2015. Epub ahead of print 5/11/15. PMID: 25964296
- Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Bitolo U, Fowler N. Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of Oncology. In Press. Epub 2015/02/26. PMID: 25712458
- Frys S*, Simons Z*, Hu Q, Bath MJ, Gu JJ*, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ. Etinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumor activity of rituximab and chemotherapy agents. British Journal of Haematology. 169:506-5019, 2015. Epub 2015/02/26 PMID: 25712263
- Castillo JJ, Chavez JC*, Hernandez-Ilizaliturri FJ, Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas: Biology and emerging therapeutic options. Expert Review in Hematology. 1-12, 2015 PMID: 25641215
- Thudium KE*, Wollenberg L, Mavis C, Gu J*, Fetterly GJ, Czuczman MS, Hernandez-Ilizaliturri FJ. Novel pharmacodynamic approach to assess Obatoclax (GX15-070) and Bortezomib (BTZ) synergism in Non-Hodgkin’s Lymphoma. Clinical Cancer Drugs. In Press.
- Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Molecular Cancer. 13:159-173, 2014. Epub 2014/06/29. PMID: 24972933
- Klanova M, Soukup T, Jaksa R, Molinsky J, Lateckova L, Maswabi B, Prukova D, Brezinova J, Vockova P, Hernandez-Ilizialiturri F, Kulvait V, Zivny J, Vokurka M, Necas E, Trneny M, Klener P. Mouse models of mantle cell lymphoma: complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Laboratory Investigation. 94(7):806-817, 2014. Epub 2014/05/28. PMID: 24862967
- Goy A, Hernandez-Ilizaliturri FJ, Kahl B, Ford P, Protomastro E, Berger M. A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leukemia and Lymphoma. Epub 2014/05/06. DOI: 10.3109/10428194.2014.907891. 55(12):2761-2768, 2014. PMID: 24679008
- Kun L, Hernandez-Ilizaliturri FJ, Reddy NM. Novel therapeutic strategies for cutaneous T-cell lymphoma in advanced stages. Semin Hematol. 51:35-41, 2014. PMID: 24468314
- Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun H, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124(15):2354-2361, 2014. PMID: 25161267
- Gandhi S*, Kallab AM, Hernandez-Ilizaliturri FJ. Diffuse large cell lymphoma. Medscape Reference. Updated 1/6/14. Available at: http://emedicine.medscape.com/article/202969-overview.
- Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Illizaliturri FJ, Feldman T, Wegner B, Myskowski PL. Final Results of Phase II trial of doxorubicin HC1 liposome injections followed by Bexarotene in Advanced Cutaneous T-Cell Lymphoma. Annals of Oncology. 25:206-210, 2014. PMID: 24285015
- Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Dagan LN, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL. Lymphoma occurring during pregnancy: Antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 31(32):4132-4139, 2013. PMID: 24043736
- Gu JJ*, Hernandez-Ilizaliturri FJ, Mavis C, Czuczman NM, Deeb G, Gibbs J, Skitzki JJ, Patil R*, Czuczman MS. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell-cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy sensitive or resistant B-cell lymphoma pre-clinical models. Anti-Cancer Drugs. 24(10):1030-1038, 2013. PMID: 23995855
- Gu JJ*, Hernandez-Ilizaliturri FJ, Kaufman GP*, Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. British journal of haematology. 162(5):657-69, 2013. PMID: 23826755
- Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, Madle H, Deeb G, Dorken B, Thome M, Lenz P, Dirnhofer S, Hernandez-Ilizaliturri FJ, Tzankov A, Lenz G. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 27(6):1381-90, 2013. PMID: 23257783
- Hernandez-Ilizaliturri FJ. The evolving role of Brentuximab vedotin in the management of CD30-positive lymphoma. Intl J of Targeted Therapies in Cancer. November, 2012:44-48.
- Hernandez-Ilizaliturri FJ. Evolving therapeutic strategies in patients with relapsed/refractory Hodgkin lymphoma. American Society of Clinical Oncology Educational Book. 2011 339-345
- Czuczman MS, Chanan-Khan AA, Skipper M, Mohr A, Bernstein ZP, Brady WE, Hernandez-Ilizaliturri FJ. Phase I/II study of rituximab in combination with liposomal doxorubicin (Doxil) in patients with relapsed/refractory B-cell lymphoma: Clinical efficacy without cardiac toxicity. Leukemia & Lymphoma. In Press.
- Hoppe RT, Advani RH, Ai WYZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H.Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 105:589-597
- Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British journal of haematology 2012;1564:490-498
- Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical cancer research 2012;184:1039-1050
- Dawar R, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best practice and research. Clinical haematology 2012; 252:185-190
- Sher T, Lee K, Iancu D, Masood A, Jamshed S, Lawrence W, Soniwala S, Sood R, Hong F, Hernandez-Ilizaliturri FJ, Czuczman MS, Wilding G, Tan W, Wood M, Manfredi D, Miller KC, Ailawadhi S, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology2011; 1541:104-110
- Wierda WG, Russell CA, Nielsen TG, Gupta I, Chan G, Chang CN, Gorczyca M, Padmanabhan S,Hernandez-Ilizaliturri FJ, Griniute R, Hess G, Smolej L, Mayer J, Stilgenbauer S, Griskevicius L, Durig J, Kipps TJ, on behalf of the 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011; 11724:6450-6458
- Vaidyanathan G, Ngamphaiboon N, Hernandez-Ilizaliturri FJ. Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature. Annals of hematology 2011; 908:955-962
- Brem EA, Czuczman MS, Fetterly G, Gibbs JF, Deeb G, Hoskin P, Mavis C, Knight J, Campagna R, Iqbal A, Gu J, Riaz W, Bhat S, Olejniczak SH, Tsai PC, Khubchandani S, Thudium K, Hernandez-Ilizaliturri FJ.Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.British journal of haematology 2011; 1535:599-611
- Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, MacOn WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 11722:5058-5066
- Hoppe RT, Advani RH, Ai WYZ, Ambinder RF, Bello CM, Bierman PJ, Blum KA, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Weiss L, Winter JN, Yahalom J. Hodgkin lymphoma.Journal of the National Comprehensive Cancer Network : JNCCN 2011; 99:1020-1058
- Castillo JJ, Ribera J-M, Pantanowitz L, Montoto S, Horwitz SM, Hernandez-Ilizaliturri F, Diez-Martin JL, Cwynarski K, Collins JA, Bower M, Bibas M, Beltran BE, Vose JM. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. American journal of hematology 2011;863:256-261
- Batoo SA, Hernandez-Ilizaliturri F. The emerging role of lenalidomide in the management of lymphoid malignancies. Therapeutic advances in hematology 2011; 21:45-53
- Chanan-Khan A, Zeldis JB, Wallace PK, Czuczman MS, Hernandez-Illatazurri F, Miller A, Padmanabhan S, Lawrence D, Miller KC, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011; 11710:2127-2135
- Chavez J, Czuczman MS, Hernandez-Ilizaliturri FJ. Biology and management of diffuse large B-cell lymphoma. Contemporary oncology 2010; 21:28-38
- Ngamphaiboon N, Pukiat S, Kandimalla Y, Hernandez-Ilizaliturri FJ, Rooney JJ. Diffuse large B-cell lymphoma presenting as pancoast tumor. Journal of clinical oncology 2010; 2816:e254-e256
- Olejniczak SH, Hernandez-Ilizaliturri FJ, Gibbs J, Clements JL, Mavis C, Riaz W, Bangia N, Belicha-Villanueva A, Blickwedehl J, Czuczman MS. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 2010; 11625:5605-5614
- Sher T, Lee K, Block AW, Wood MT, Sood R, Bilgrami SA, Lawrence W, Miller A, Czuczman MS,Hernandez-Ilizaliturri F, Whitworth A, Lawrence D, Miller KC, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and lymphoma2010; 511:85-88
- Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leukemia and lymphoma 2010; 51Suppl. 1:1-10
- Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic research 2010; 461-3:192-205
- Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current opinion in investigational drugs (London, England : 2000) 2009; 106:579-587
- Gerber H-P, Benjamin D, Carter PJ, McDonagh CF, Hernandez-Ilizaliturri FJ, Hayes B, Okeley N, Alley SC, McCormick R, Miyamoto J, Morris-Tilden C, Stone I, Kung-Sutherland M, Grewal IS. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009; 11318:4352-4361
- Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Francisco JH-I, Hansen HJ, Chang C-H.Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 1135:1062-1070
- Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park, N.Y.) 2009; 236:546-553
- Hernandez-Ilizaliturri FJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park, N.Y.) 2009; 237:610-615
- Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical cancer research 2008; 145:1550-1560
- Hoppe RT, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, Kaminski MS, Hudson MM, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, National Comprehensive Cancer Network. Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN 2008; 66:594-622
- Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS.Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British journal of haematology 2008; 1401:36-45
- Benekli M, McCarthy PL Jr, Padmanabhan S, Battiwalla M, Bambach B, Hernandez-Ilizaliturri F, Czuczman MS, Younis T, Smiley SL, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone marrow transplantation 2008;417:613-619
- Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma.Clinical lymphoma and myeloma 2008; 85:277-282
- Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clinical cancer research 2007; 1315 Pt 1:4556-4564
- Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia and lymphoma 2007; 4812:2424-2436
Darwar R* and Hernandez-Ilizaliturri FJ. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Practice & Research Clinical Haematology 25(2):185-190, 2012. PMID: 22687454